Early switch strategy in patients with major depressive disorder

References

• Fava M, Rush AJ, Trivedi MH et al. Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. Psychiatr. Clin. North Am. 26(2), 457–494, x (2003).
   PubMed Web of Science ®Google Scholar
• Trivedi MH, Rush AJ, Wisniewski SR et al. ; STAR*D Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am. J. Psychiatry 163(1), 28–40 (2006).
   PubMed Web of Science ®Google Scholar
• Rush AJ, Trivedi MH, Wisniewski SR et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am. J. Psychiatry 163(11), 1905–1917 (2006).
   PubMed Web of Science ®Google Scholar
• Pae CU, Forbes A, Patkar AA. Aripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data. CNS Drugs 25(2), 109–127 (2011).
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder (revision). Am. J. Psychiatry 157(4 Suppl.), 1–45 (2000).
   Google Scholar
• Nierenberg AA, Farabaugh AH, Alpert JE et al. Timing of onset of antidepressant response with fluoxetine treatment. Am. J. Psychiatry 157(9), 1423–1428 (2000).
   PubMed Web of Science ®Google Scholar
• Szegedi A, Müller MJ, Anghelescu I, Klawe C, Kohnen R, Benkert O. Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression. J. Clin. Psychiatry 64(4), 413–420 (2003).
   PubMed Web of Science ®Google Scholar
• Posternak MA, Zimmerman M. Is there a delay in the antidepressant effect? A meta-analysis. J. Clin. Psychiatry 66(2), 148–158 (2005).
   PubMed Web of Science ®Google Scholar
• Taylor MJ, Freemantle N, Geddes JR, Bhagwagar Z. Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis. Arch. Gen. Psychiatry 63(11), 1217–1223 (2006).
   PubMed Web of Science ®Google Scholar
• Papakostas GI, Perlis RH, Scalia MJ, Petersen TJ, Fava M. A meta-analysis of early sustained response rates between antidepressants and placebo for the treatment of major depressive disorder. J. Clin. Psychopharmacol. 26(1), 56–60 (2006).
   PubMed Web of Science ®Google Scholar
• van Calker D, Zobel I, Dykierek P et al. Time course of response to antidepressants: predictive value of early improvement and effect of additional psychotherapy. J. Affect. Disord. 114(1–3), 243–253 (2009).
   PubMed Web of Science ®Google Scholar
• Henkel V, Seemüller F, Obermeier M et al. Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression. J. Affect. Disord. 115(3), 439–449 (2009).
   PubMed Web of Science ®Google Scholar
• Lin CH, Lane HY, Chen CC, Juo SH, Yen CF. Early prediction of fluoxetine response for Han Chinese inpatients with major depressive disorder. J. Clin. Psychopharmacol. 31(2), 187–193 (2011).
   PubMed Web of Science ®Google Scholar
• Tadic A, Helmreich I, Mergl R et al. Early improvement is a predictor of treatment outcome in patients with mild major, minor or subsyndromal depression. J. Affect. Disord. 120(1–3), 86–93 (2010).
   PubMed Web of Science ®Google Scholar
• Romera I, Pérez V, Menchón JM et al. Early Switch Strategy in Patients With Major Depressive Disorder: A Double-Blind, Randomized Study. J. Clin. Psychopharmacol. 32(4), 479–486 (2012).
   PubMed Web of Science ®Google Scholar
• Rush AJ, Warden D, Wisniewski SR et al. STAR*D: revising conventional wisdom. CNS Drugs 23(8), 627–647 (2009).
   PubMed Web of Science ®Google Scholar
• Nierenberg AA, McLean NE, Alpert JE, Worthington JJ, Rosenbaum JF, Fava M. Early nonresponse to fluoxetine as a predictor of poor 8-week outcome. Am. J. Psychiatry 152(10), 1500–1503 (1995).
   PubMed Web of Science ®Google Scholar
• Papakostas GI, Petersen T, Sklarsky KG, Nierenberg AA, Alpert JE, Fava M. Timing of clinical improvement and symptom resolution in the treatment of major depressive disorder. Psychiatry Res. 149(1–3), 195–200 (2007).
   PubMed Web of Science ®Google Scholar
• Tedeschini E, Fava M, Papakostas GI. Placebo-controlled, antidepressant clinical trials cannot be shortened to less than 4 weeks’ duration: a pooled analysis of randomized clinical trials employing a diagnostic odds ratio-based approach. J. Clin. Psychiatry 72(1), 98–118 (2011).
   PubMed Web of Science ®Google Scholar
• Nierenberg AA, Quitkin FM, Kremer C, Keller MB, Thase ME. Placebo-controlled continuation treatment with mirtazapine: acute pattern of response predicts relapse. Neuropsychopharmacology 29(5), 1012–1018 (2004).
   PubMed Web of Science ®Google Scholar